Combination product for the treatment of neurological and/or psychiatric disorders
Inventors
PEREZ CASTILLO, ANA MARIA • RIBA SERRANO, Jordi • Morales García, Jose Ángel
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11723894-B2
Publication Date
2023-08-15
Expiration Date
Abstract
The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.
Core Innovation
The disclosed invention relates to a pharmaceutical combination product for treating and/or preventing neurological and psychiatric disorders. The combination product includes a compound described by formula (I), or a salt thereof, and a 5-HT2A receptor antagonist, and optionally a monoamine oxidase inhibitor.
The compounds encompassed by formula (I) are hallucinogenic/psychedelic tryptamine-related entities, with embodiments including N,N-dimethyltryptamine (DMT) and related N-alkylated tryptamines. The invention positions these tryptamine compounds as neurogenesis-promoting agents, including effects on adult neural stem cells and neurospheres, and relates such activity to Sigma-1 receptor involvement.
The invention frames the combination as addressing a balance between neurogenesis promotion and side-effect control by using 5-HT2A receptor antagonism to prevent and/or alleviate hallucinogenic/psychedelic side effects produced by the formula (I) compound. The documented support also associates the approach with anti-inflammatory and dopaminergic neuroprotection in Parkinson’s disease models while the 5-HT2A antagonist blocks hallucinogenic/psychedelic side effects.
Claims Coverage
Independent claim clm-00001 covers a pharmaceutical combination product built from two core inventive ingredient categories, a formula (I) compound and a 5-HT2A receptor antagonist, with an optional monoamine oxidase inhibitor.
Pharmaceutical combination product of formula (I) and 5-HT2A receptor antagonist
A pharmaceutical combination product consisting of a compound described by formula (I), or salt thereof, and a 5-HT2A receptor antagonist, wherein substituent groups R1, R2, R3, and R4 are selected from the recited groups and R5 is selected from deuterium or protium.
Optional monoamine oxidase inhibitor inclusion
The pharmaceutical combination product further optionally comprises a monoamine oxidase inhibitor in combination with the formula (I) compound and the 5-HT2A receptor antagonist.
The essential inventive concept is pairing a formula (I) hallucinogenic/psychedelic tryptamine compound, or salt thereof, with a 5-HT2A receptor antagonist, optionally together with a monoamine oxidase inhibitor.
Stated Advantages
Alleviating and/or preventing hallucinogenic and/or psychedelic side effects caused by the compound described by formula (I) using the 5-HT2A receptor antagonist.
Promoting neurogenesis while preserving the neurogenesis-associated effects in the presence of a 5-HT2A receptor antagonist.
Providing anti-inflammatory and dopaminergic neuroprotection in Parkinson’s disease models while the 5-HT2A antagonist blocks hallucinogenic/psychedelic side effects.
Documented Applications
Treatment and/or prevention of neurological and psychiatric disorders, including psychiatric disorders and neurological disorders in humans.
Treatment and/or prevention in Parkinson’s disease models, described as involving anti-inflammatory and dopaminergic neuroprotection.
Treatment and/or prevention relating to Alzheimer’s disease, as included in the documented support scope mentioned in the partial content.
Interested in licensing this patent?